US6365178B1
(en)
*
|
1996-09-06 |
2002-04-02 |
Watson Pharmaceuticals, Inc. |
Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
US7629384B2
(en)
*
|
1997-09-17 |
2009-12-08 |
Strategic Science & Technologies, Llc |
Topical delivery of L-arginine to cause beneficial effects
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
EP1117389A1
(en)
*
|
1998-09-08 |
2001-07-25 |
TheraTech, Inc. |
Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs
|
GB9828480D0
(en)
*
|
1998-12-24 |
1999-02-17 |
Dermatech Limited |
Transdermal drug delivery system
|
US6586000B2
(en)
*
|
1999-12-16 |
2003-07-01 |
Dermatrends, Inc. |
Hydroxide-releasing agents as skin permeation enhancers
|
US6582724B2
(en)
*
|
1999-12-16 |
2003-06-24 |
Dermatrends, Inc. |
Dual enhancer composition for topical and transdermal drug delivery
|
US6562368B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
|
US6645520B2
(en)
*
|
1999-12-16 |
2003-11-11 |
Dermatrends, Inc. |
Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
|
US6558695B2
(en)
*
|
1999-12-16 |
2003-05-06 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
|
US6562369B2
(en)
*
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
|
US20030104041A1
(en)
*
|
1999-12-16 |
2003-06-05 |
Tsung-Min Hsu |
Transdermal and topical administration of drugs using basic permeation enhancers
|
US6719997B2
(en)
|
2000-06-30 |
2004-04-13 |
Dermatrends, Inc. |
Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
|
US6565879B1
(en)
|
1999-12-16 |
2003-05-20 |
Dermatrends, Inc. |
Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
|
US6602912B2
(en)
|
2000-06-30 |
2003-08-05 |
Dermatrends, Inc. |
Transdermal administration of phenylpropanolamine
|
US6673363B2
(en)
*
|
1999-12-16 |
2004-01-06 |
Dermatrends, Inc. |
Transdermal and topical administration of local anesthetic agents using basic enhancers
|
US6562370B2
(en)
|
1999-12-16 |
2003-05-13 |
Dermatrends, Inc. |
Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
DE10004790B4
(de)
*
|
2000-02-01 |
2004-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
|
US6642304B1
(en)
|
2000-02-25 |
2003-11-04 |
3M Innovative Properties Company |
Polyurethane-based adhesives, systems for such adhesives, articles therefrom, and methods of making
|
US6518359B1
(en)
|
2000-02-25 |
2003-02-11 |
3M Innovative Properties Co. |
Polyurethane-based pressure-sensitive adhesives, systems for such adhesives, articles therefrom, and methods of making
|
US20030124177A1
(en)
*
|
2000-04-26 |
2003-07-03 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
CN1438861A
(zh)
|
2000-04-26 |
2003-08-27 |
沃特森药物公司 |
最小化与奥昔布宁疗法有关的副作用
|
US7029694B2
(en)
|
2000-04-26 |
2006-04-18 |
Watson Laboratories, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US7179483B2
(en)
*
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
KR100732948B1
(ko)
*
|
2000-11-22 |
2007-06-27 |
아이큐어 주식회사 |
국소마취용 패취
|
US20050208117A1
(en)
*
|
2001-03-16 |
2005-09-22 |
Venkatraman Subramanian S |
Transdermal administration of fentanyl and analogs thereof
|
CA2440884C
(en)
*
|
2001-03-16 |
2012-05-22 |
Alza Corporation |
Transdermal patch for administering fentanyl
|
DE20221397U1
(de)
|
2001-03-16 |
2005-10-20 |
Alza Corp., Mountain View |
Transdermal-Pflaster zum Verabreichen von Fentanyl
|
EP1423116A1
(en)
*
|
2001-08-14 |
2004-06-02 |
Biotie Therapies Corp. |
Method of treating alcoholism or alcohol abuse
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
WO2003032916A2
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
US20050226915A1
(en)
*
|
2001-12-28 |
2005-10-13 |
Oramelts Corporation, A Washington Corporation |
Method for manufacturing and packaging oral patches with rounded edges
|
US20030124178A1
(en)
*
|
2001-12-28 |
2003-07-03 |
Haley Jeffrey T. |
Soft, adherent, soluble oral patch
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
JP2005526839A
(ja)
*
|
2002-04-23 |
2005-09-08 |
アルザ・コーポレーシヨン |
不正使用の可能性が低い経皮鎮痛薬システム
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
DE60326354D1
(de)
*
|
2002-08-20 |
2009-04-09 |
Euro Celtique Sa |
Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
|
US20040086551A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Miller Kenneth J. |
Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
|
US7182955B2
(en)
*
|
2003-04-30 |
2007-02-27 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
ME00276B
(me)
|
2003-04-30 |
2011-05-10 |
Purdue Pharma Lp |
Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US20040219195A1
(en)
*
|
2003-04-30 |
2004-11-04 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
JP4847868B2
(ja)
*
|
2003-05-14 |
2011-12-28 |
ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド |
化合物、及び、アミロイドベータの調節におけるその使用
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
EP1677771A2
(en)
|
2003-10-30 |
2006-07-12 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
US20050137375A1
(en)
*
|
2003-12-19 |
2005-06-23 |
3M Innovative Properties Company |
Polyurethane-based pressure sensitive adhesives and methods of manufacture
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
ES2429443T3
(es)
*
|
2004-04-19 |
2013-11-14 |
Strategic Science & Technologies, Llc |
Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
|
US9226909B2
(en)
|
2004-04-19 |
2016-01-05 |
Strategic Science & Technologies, Llc |
Beneficial effects of increasing local blood flow
|
WO2005112913A1
(en)
|
2004-05-20 |
2005-12-01 |
The Scripps Research Institute |
Transthyretin stabilization
|
US7666914B2
(en)
*
|
2004-06-03 |
2010-02-23 |
Richlin David M |
Topical preparation and method for transdermal delivery and localization of therapeutic agents
|
WO2006009876A2
(en)
*
|
2004-06-17 |
2006-01-26 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
JP2008505916A
(ja)
*
|
2004-07-09 |
2008-02-28 |
メタバシス・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの酸素/窒素複素環阻害剤
|
JP4824963B2
(ja)
*
|
2004-08-12 |
2011-11-30 |
日東電工株式会社 |
貼付材及び貼付製剤
|
JP4745747B2
(ja)
|
2004-08-12 |
2011-08-10 |
日東電工株式会社 |
フェンタニル含有貼付製剤
|
JP2008510713A
(ja)
*
|
2004-08-20 |
2008-04-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
半透明保護フィルムを有する経皮薬物送達デバイス
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
US8440705B2
(en)
|
2004-09-17 |
2013-05-14 |
Whitehead Institute For Biomedical Research |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
US20060134201A1
(en)
*
|
2004-12-16 |
2006-06-22 |
Haley Jeffrey T |
Collagen troches for treating mouth lesions
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
JP5242375B2
(ja)
|
2005-04-01 |
2013-07-24 |
ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア |
ホスホノ−ペント−2−エン−1−イルヌクレオシド及び類似体
|
WO2006134937A1
(ja)
*
|
2005-06-14 |
2006-12-21 |
Sekisui Chemical Co., Ltd. |
皮膚外用剤
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
US10137135B2
(en)
*
|
2005-08-15 |
2018-11-27 |
Allergan Sales, Llc |
Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
EP1937226A2
(en)
*
|
2005-09-23 |
2008-07-02 |
Alza Corporation |
Transdermal galantamine delivery system
|
WO2007035940A2
(en)
*
|
2005-09-23 |
2007-03-29 |
Alza Corporation |
Transdermal norelgestromin delivery system
|
EP2308480B1
(en)
*
|
2005-09-23 |
2014-08-13 |
ALZA Corporation |
High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
|
JP2009516718A
(ja)
*
|
2005-11-23 |
2009-04-23 |
ウニベルジテート チューリッヒ |
経皮アレルゲン投与によるアレルギー治療
|
US8349120B2
(en)
*
|
2006-03-07 |
2013-01-08 |
Ora Health Corporation |
Multi-layer patch made on a sheet and enclosed in a blister
|
EA200870385A1
(ru)
*
|
2006-03-29 |
2009-04-28 |
Фолдркс Фармасьютикалз, Инк. |
Ингибирование токсичности альфа-синуклеина
|
US20070248654A1
(en)
*
|
2006-04-21 |
2007-10-25 |
Haley Jeffrey T |
Protective mouth sore discs made with corn starch
|
US20070248655A1
(en)
*
|
2006-04-21 |
2007-10-25 |
Haley Jeffrey T |
Lenticular shaped protective mouth sore discs
|
DE102006019293A1
(de)
*
|
2006-04-21 |
2007-10-25 |
LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH |
Pflaster, enthaltend ein Fentanyl Analogum
|
SI2054031T1
(sl)
|
2006-07-21 |
2016-09-30 |
Biodelivery Sciences International, Inc. |
Transmukozne naprave za administracijo z izboljšanim vnosom
|
AU2007290570C1
(en)
|
2006-08-28 |
2013-08-15 |
Kyowa Kirin Co., Ltd. |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
US20080226702A1
(en)
*
|
2007-03-16 |
2008-09-18 |
Endo Pharmaceuticals, Inc. |
Transdermal Delivery Form Disposal Systems and Methods
|
US20090018154A1
(en)
*
|
2007-05-17 |
2009-01-15 |
Endo Pharmaceuticals, Inc., A Corporation Of Delaware |
Opioid and methods of making and using the same
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
RU2499583C2
(ru)
*
|
2007-10-15 |
2013-11-27 |
Алза Корпорейшн |
Заместительное трансдермальное введение фентанила один раз в день
|
CA2706465A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of ssao/vap-1 and uses therefor
|
US9700552B2
(en)
*
|
2008-02-28 |
2017-07-11 |
Syntropharma Limited |
Pharmaceutical compositions for treatment of addiction
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
US11016104B2
(en)
|
2008-07-01 |
2021-05-25 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
US20100221313A1
(en)
*
|
2008-12-01 |
2010-09-02 |
Innovative Pharmaceuticals, Llc |
Transdermal reservoir patch
|
CN102300989B
(zh)
|
2009-01-06 |
2015-12-09 |
柯尔朗恩有限责任公司 |
用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
|
BRPI1007379B8
(pt)
|
2009-01-06 |
2022-07-19 |
Curemark Llc |
composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
|
CA2752885A1
(en)
*
|
2009-02-27 |
2010-09-02 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
WO2010111346A2
(en)
*
|
2009-03-24 |
2010-09-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Hep-lock and iv site dry mitt
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
ES2607476T3
(es)
|
2009-06-24 |
2017-03-31 |
Strategic Science & Technologies, Llc |
Composición tópica que contiene ibuprofeno
|
EP2445493A1
(en)
|
2009-06-24 |
2012-05-02 |
Strategic Science & Technologies, LLC |
Topical composition containing naproxen
|
US11684624B2
(en)
|
2009-06-24 |
2023-06-27 |
Strategic Science & Technologies, Llc |
Treatment of erectile dysfunction and other indications
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
US8710092B2
(en)
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
JP5927506B2
(ja)
|
2010-04-13 |
2016-06-01 |
レルマダ セラピューティクス、インク. |
1−メチル−2’,6’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
|
EP3721893A1
(en)
|
2010-12-29 |
2020-10-14 |
Strategic Science & Technologies, LLC |
Treatment of erectile dysfunction
|
JP2014501283A
(ja)
|
2010-12-29 |
2014-01-20 |
ストラテジック サイエンス アンド テクノロジーズ, エルエルシー |
アレルギーおよび他の適応症の処置のためのシステムおよび方法
|
EP2701733B1
(en)
|
2011-04-21 |
2019-04-03 |
Curemark, LLC |
Compounds for the treatment of neuropsychiatric disorders
|
US9925264B2
(en)
|
2011-05-10 |
2018-03-27 |
Itochu Chemical Frontier Corporation |
Non-aqueous patch
|
US11786455B2
(en)
|
2011-05-10 |
2023-10-17 |
Itochu Chemical Frontier Corporation |
Non-aqueous patch
|
MX349572B
(es)
|
2011-05-10 |
2017-08-03 |
Itochu Chemical Frontier Corp |
Parche no acuoso.
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
EA201991223A1
(ru)
|
2011-08-18 |
2019-10-31 |
|
Не вызывающие зависимость мукоадгезивные устройства для доставки бупренорфина
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
EP3363432B1
(en)
|
2011-09-27 |
2020-12-23 |
Itochu Chemical Frontier Corporation |
Non-aqueous patch
|
CA2790749A1
(en)
*
|
2011-09-29 |
2013-03-29 |
Nitto Denko Corporation |
Manufacturing method of patch preparation
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
WO2013095708A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
RS57086B1
(sr)
|
2012-05-02 |
2018-06-29 |
Boehringer Ingelheim Int |
Supstituisani 3-haloalilamin inhibitori ssao i njihova primena
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
EP2861562B1
(en)
|
2012-06-14 |
2018-05-09 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
US9364273B2
(en)
|
2012-08-15 |
2016-06-14 |
DePuy Synthes Products, Inc. |
Drug eluting surgical screw
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
WO2014068600A1
(en)
|
2012-11-02 |
2014-05-08 |
Zydus Technologies Limited |
Stable transdermal pharmaceutical drug delivery system comprising diclofenac
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
NOVEL DERIVATIVES OF METHYSERGIDE
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014210504A1
(en)
*
|
2013-06-28 |
2014-12-31 |
Mitroo Sumair |
Tape having transdermal analgesic properties
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
US10238648B2
(en)
|
2014-07-18 |
2019-03-26 |
Buzzz Pharmaceuticals Ltd. |
Abuse deterrent opioid/opioid-antagonist transdermal patch
|
WO2016025129A1
(en)
|
2014-08-14 |
2016-02-18 |
Alhamadsheh Mamoun M |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
HUE048569T2
(hu)
*
|
2014-12-18 |
2020-07-28 |
Icure Pharm Inc |
Hatóanyagként donepezilt tartalmazó transzdermális készítmény
|
US10221248B2
(en)
|
2014-12-22 |
2019-03-05 |
The Rockefeller University |
Anti-MERTK agonistic antibodies and uses thereof
|
US10010543B1
(en)
|
2014-12-23 |
2018-07-03 |
Barr Laboratories, Inc. |
Transdermal dosage form
|
US9657020B2
(en)
|
2015-01-20 |
2017-05-23 |
Xoc Pharmaceuticals, Inc. |
Ergoline compounds and uses thereof
|
CN107405346A
(zh)
|
2015-01-20 |
2017-11-28 |
Xoc制药股份有限公司 |
异麦角灵化合物及其用途
|
SG10201907901XA
(en)
|
2015-03-03 |
2019-10-30 |
Kymab Ltd |
Antibodies, uses & methods
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
WO2017151836A1
(en)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
JP2019510085A
(ja)
|
2016-03-08 |
2019-04-11 |
ロス ガトス ファーマスーティカルズ, インク.Los Gatos Pharmaceuticals, Inc. |
癌治療のためのナノ粒子ならびに方法および化合物
|
WO2017156183A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
EP3454904B1
(en)
|
2016-05-13 |
2022-12-14 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
EP3526256A1
(en)
|
2016-10-11 |
2019-08-21 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
CA3053332A1
(en)
|
2017-02-17 |
2018-08-23 |
CAMRIS International, Inc. |
Universal antivenom
|
JP7157752B2
(ja)
|
2017-02-17 |
2022-10-20 |
エイドス セラピューティクス,インコーポレイティド |
Ag-10、その中間体及びその塩の調製方法
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
ES2952961T3
(es)
|
2017-05-01 |
2023-11-07 |
Agenus Inc |
Anticuerpos anti-TIGIT y métodos de uso de los mismos
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
JP2020522504A
(ja)
|
2017-06-01 |
2020-07-30 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc |
多環式化合物およびそれらの用途
|
EP3645029B1
(en)
|
2017-06-26 |
2023-01-18 |
Institut Pasteur |
Treatments to eliminate hiv reservoirs and reduce viral load
|
JP7076059B2
(ja)
|
2017-06-27 |
2022-05-27 |
ニューラクル サイエンス カンパニー リミテッド |
抗fam19a5抗体及びその用途
|
KR102472683B1
(ko)
|
2017-06-27 |
2022-12-01 |
주식회사 뉴라클사이언스 |
녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
|
WO2019003159A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
|
EP3645040A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US20190175519A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Teikoku Pharma Usa, Inc. |
Naloxone Transdermal Delivery Devices and Methods for Using the Same
|
MX2020009844A
(es)
|
2018-03-23 |
2021-01-15 |
Eidos Therapeutics Inc |
Metodos para tratar amiloidosis por transtiretina (ttr) usando ag10.
|
JP7171081B2
(ja)
|
2018-04-24 |
2022-11-15 |
ニューラクル サイエンス カンパニー リミテッド |
神経病性疼痛の治療のための配列類似性19、メンバーa5抗体を有する抗ファミリーの用途
|
WO2020008370A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal patch
|
WO2020009685A1
(en)
|
2018-07-02 |
2020-01-09 |
John Tang |
Transdermal dosage form
|
WO2020008366A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal dosage form
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
BR112020026493A2
(pt)
|
2018-08-17 |
2021-03-23 |
Eidos Therapeutics, Inc. |
Formulações de ag10
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
AU2019379325A1
(en)
|
2018-11-16 |
2021-06-03 |
Genexine, Inc. |
Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
CA3138403A1
(en)
|
2019-05-20 |
2020-11-26 |
Christopher J. MACNEVIN |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
EP4031534A1
(en)
|
2019-09-16 |
2022-07-27 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
WO2021146191A1
(en)
|
2020-01-13 |
2021-07-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
|
US20230210952A1
(en)
|
2020-02-05 |
2023-07-06 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
TW202203921A
(zh)
*
|
2020-03-30 |
2022-02-01 |
美商神經治療有限責任公司 |
右美沙芬之經皮輸送技術
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
KR20230098201A
(ko)
|
2020-10-26 |
2023-07-03 |
네오이뮨텍, 인코퍼레이티드 |
줄기 세포 동원의 유도 방법
|
KR20230104176A
(ko)
|
2020-11-02 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
코로나바이러스의 치료를 위한 인터류킨-7의 용도
|
AU2021376396A1
(en)
|
2020-11-05 |
2023-06-08 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
CN117642396A
(zh)
|
2021-03-10 |
2024-03-01 |
戴斯分子Sv有限公司 |
αVβ6和αVβ1整联蛋白抑制剂及其用途
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|